None
Quote | Akebia Therapeutics Inc. (NASDAQ:AKBA)
Last: | $1.44 |
---|---|
Change Percent: | -2.7% |
Open: | $1.52 |
Close: | $1.44 |
High: | $1.52 |
Low: | $1.41 |
Volume: | 1,132,793 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
News | Akebia Therapeutics Inc. (NASDAQ:AKBA)
2024-07-11 07:53:35 ET More on Akebia, CSL, etc. Akebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Call Transcript Bird flu shots to begin in Finland CSL Seqirus to provide more than 40M bird flu vaccine doses to Europe Seeking Alpha’s Quant Rating on ...
Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets PR Newswire Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement wit...
Message Board Posts | Akebia Therapeutics Inc. (NASDAQ:AKBA)
Subject | By | Source | When |
---|---|---|---|
Nice rise from .50s past few weeks. Pump | tw0122 | investorshub | 04/28/2023 11:22:27 AM |
Bought a lot here today. | Afterhoursearnings3 | investorshub | 03/09/2023 7:44:45 PM |
two hedge funds competing to be largest $AKBA | shurtha2000 | investorshub | 03/02/2023 4:04:38 PM |
Nice find G2G. :) | subslover | investorshub | 02/24/2023 12:57:07 PM |
$AKBA 2NEWS 2DAY | TheFinalCD | investorshub | 02/24/2023 12:12:44 AM |
News, Short Squeeze, Breakout and More Instantly...
Akebia Therapeutics Inc. Company Name:
AKBA Stock Symbol:
NASDAQ Market:
Akebia Therapeutics Inc. Website:
Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets PR Newswire Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement wit...
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference PR Newswire CAMBRIDGE, Mass. , June 27, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purp...
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer PR Newswire CAMBRIDGE, Mass. , June 24, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with t...